A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens
Nasopharyngeal cancer (NPC) is a prevalent type of cancer that often takes the form of undifferentiated carcinoma in the Maghreb region. It affects people of all ages. NPC diagnosis, mainly based on detecting Epstein-Barr virus (EBV), has not been well evaluated in North Africa. We compared the clas...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/15/11/2158 |
| _version_ | 1797457552651321344 |
|---|---|
| author | Hamid Melouli Abdelhalim Khenchouche Fouzia Taibi-Zidouni Dahmani Salma Nassim Aoudia Djamel Djennaoui Tewfik Sahraoui Samir Benyahia Fatima Zohra El Kebir |
| author_facet | Hamid Melouli Abdelhalim Khenchouche Fouzia Taibi-Zidouni Dahmani Salma Nassim Aoudia Djamel Djennaoui Tewfik Sahraoui Samir Benyahia Fatima Zohra El Kebir |
| author_sort | Hamid Melouli |
| collection | DOAJ |
| description | Nasopharyngeal cancer (NPC) is a prevalent type of cancer that often takes the form of undifferentiated carcinoma in the Maghreb region. It affects people of all ages. NPC diagnosis, mainly based on detecting Epstein-Barr virus (EBV), has not been well evaluated in North Africa. We compared the classical EBV serological tests using indirect immunofluorescence to the detection of EBV DNase antibodies by immunoblot in Algerian NPC patients. Significant variations were observed among different age groups of patients regarding the presence of VCA-IgA antibodies (0–14 and ≥30 years old, <i>p</i> < 0.0001; 15–19 and ≥30 years old, <i>p</i> < 0.01) and EA-IgA (0–14 and ≥30 years old, <i>p</i> < 0.01; 15–29 and ≥30 years old, <i>p</i> < 0.05). Differences were also noted in the titers of IgA anti-VCA and anti-EA antibodies across the three age groups. Some patients under the age of 30 with detectable IgG anti-VCA antibodies had undetectable IgA anti-VCA antibodies. These patients had a strong anti-DNase IgA response. However, older individuals had a higher level of anti-DNase IgG. Before treatment, children had strong DNase reactivity as indicated by specific IgA antibodies. Young adults had high IgA anti-DNase response, but the elderly (90.9%) had a lower response for these antibodies. Following therapy, the children retained high levels of IgA anti-DNase antibodies, and 66% of the young adults demonstrated robust antibody reactivity against DNase. In contrast, IgG responses to anti-DNase were low in children. This study demonstrated the utility of anti-DNase responses in the diagnosis and prognosis of NPC. |
| first_indexed | 2024-03-09T16:23:41Z |
| format | Article |
| id | doaj.art-795cf11a0533419bbc4804663d6f0ed2 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T16:23:41Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-795cf11a0533419bbc4804663d6f0ed22023-11-24T15:10:35ZengMDPI AGViruses1999-49152023-10-011511215810.3390/v15112158A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical AntigensHamid Melouli0Abdelhalim Khenchouche1Fouzia Taibi-Zidouni2Dahmani Salma3Nassim Aoudia4Djamel Djennaoui5Tewfik Sahraoui6Samir Benyahia7Fatima Zohra El Kebir8Viral Oncogenesis Laboratory, Pasteur Institute of Algeria, Algiers 16000, AlgeriaLaboratory of Applied Biochemistry, Ferhat Abbas, Setif 1 University, Setif 19000, AlgeriaViral Oncogenesis Laboratory, Pasteur Institute of Algeria, Algiers 16000, AlgeriaViral Oncogenesis Laboratory, Pasteur Institute of Algeria, Algiers 16000, AlgeriaViral Oncogenesis Laboratory, Pasteur Institute of Algeria, Algiers 16000, AlgeriaOtorhinolaryngology Department, Mustapha Pacha Hospital, Algiers 16000, AlgeriaLaboratory of Developmental Biology and Differentiation, Es-Sénia University, Oran 31000, AlgeriaOtorhinolaryngology Department, Mustapha Pacha Hospital, Algiers 16000, AlgeriaLaboratory of Developmental Biology and Differentiation, Es-Sénia University, Oran 31000, AlgeriaNasopharyngeal cancer (NPC) is a prevalent type of cancer that often takes the form of undifferentiated carcinoma in the Maghreb region. It affects people of all ages. NPC diagnosis, mainly based on detecting Epstein-Barr virus (EBV), has not been well evaluated in North Africa. We compared the classical EBV serological tests using indirect immunofluorescence to the detection of EBV DNase antibodies by immunoblot in Algerian NPC patients. Significant variations were observed among different age groups of patients regarding the presence of VCA-IgA antibodies (0–14 and ≥30 years old, <i>p</i> < 0.0001; 15–19 and ≥30 years old, <i>p</i> < 0.01) and EA-IgA (0–14 and ≥30 years old, <i>p</i> < 0.01; 15–29 and ≥30 years old, <i>p</i> < 0.05). Differences were also noted in the titers of IgA anti-VCA and anti-EA antibodies across the three age groups. Some patients under the age of 30 with detectable IgG anti-VCA antibodies had undetectable IgA anti-VCA antibodies. These patients had a strong anti-DNase IgA response. However, older individuals had a higher level of anti-DNase IgG. Before treatment, children had strong DNase reactivity as indicated by specific IgA antibodies. Young adults had high IgA anti-DNase response, but the elderly (90.9%) had a lower response for these antibodies. Following therapy, the children retained high levels of IgA anti-DNase antibodies, and 66% of the young adults demonstrated robust antibody reactivity against DNase. In contrast, IgG responses to anti-DNase were low in children. This study demonstrated the utility of anti-DNase responses in the diagnosis and prognosis of NPC.https://www.mdpi.com/1999-4915/15/11/2158undifferentiated nasopharyngeal carcinomadiagnosisEBVVCAEADNase |
| spellingShingle | Hamid Melouli Abdelhalim Khenchouche Fouzia Taibi-Zidouni Dahmani Salma Nassim Aoudia Djamel Djennaoui Tewfik Sahraoui Samir Benyahia Fatima Zohra El Kebir A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens Viruses undifferentiated nasopharyngeal carcinoma diagnosis EBV VCA EA DNase |
| title | A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens |
| title_full | A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens |
| title_fullStr | A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens |
| title_full_unstemmed | A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens |
| title_short | A Distinct Anti-EBV DNase Profile in Patients with Undifferentiated Nasopharyngeal Carcinoma Compared to Classical Antigens |
| title_sort | distinct anti ebv dnase profile in patients with undifferentiated nasopharyngeal carcinoma compared to classical antigens |
| topic | undifferentiated nasopharyngeal carcinoma diagnosis EBV VCA EA DNase |
| url | https://www.mdpi.com/1999-4915/15/11/2158 |
| work_keys_str_mv | AT hamidmelouli adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT abdelhalimkhenchouche adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT fouziataibizidouni adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT dahmanisalma adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT nassimaoudia adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT djameldjennaoui adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT tewfiksahraoui adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT samirbenyahia adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT fatimazohraelkebir adistinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT hamidmelouli distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT abdelhalimkhenchouche distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT fouziataibizidouni distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT dahmanisalma distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT nassimaoudia distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT djameldjennaoui distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT tewfiksahraoui distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT samirbenyahia distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens AT fatimazohraelkebir distinctantiebvdnaseprofileinpatientswithundifferentiatednasopharyngealcarcinomacomparedtoclassicalantigens |